American heart journal · 2026
Prognostic impact of combined inflammatory markers in patients undergoing percutaneous coronary intervention.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Di Muro Francesca Maria, Raona Valeria, Sartori Samantha, Smith Kenneth, Oliva Angelo, Cohen Rebecca M, Gitto Mauro, Bay Benjamin, Krishnan Prakash, Sweeny Joseph, Moreno Pedro, Dangas George, Kini Annapoorna, Sharma Samin, Mehran Roxana
Аннотация
BACKGROUND AND AIM: Inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and the neutrophil-to-lymphocyte ratio (NLR) have been individually associated with cardiovascular risk in patients undergoing percutaneous coronary intervention (PCI). However, their combined prognostic value remains incompletely defined.
METHODS: Consecutive patients undergoing PCI between 2012 and 2022 were included and stratified according to baseline hs-CRP (≥2 mg/L vs <2 mg/L) and NLR (≥75th vs <75th percentile). The primary endpoint was 1-year major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to assess associations after adjustment for confounders.
RESULTS: Among 7,303 included patients, those with concomitantly elevated NLR and hs-CRP exhibited the highest incidence of overall MACE, followed by patients with only one elevated inflammatory marker, while the lowest event rates were observed in those with both markers below threshold. No significant interaction between NLR and hs-CRP was observed (P = .451). Elevated NLR was associated with a higher risk of MACE in both hs-CRP strata (hs-CRP ≥2 mg/L: hazard ratio 1.83, 95% confidence interval 1.42-2.35, P < .001; hs-CRP <2 mg/L: hazard ratio 1.55, 95% confidence interval 1.10-2.17, P = .012). After multivariable adjustment, this association remained significant only in patients with hs-CRP ≥2 mg/L, driven primarily by all-cause mortality and myocardial infarction.
CONCLUSION: In patients undergoing PCI, elevated NLR identifies a gradient of increasing risk, particularly when combined with hs-CRP ≥2 mg/L. A dual-marker inflammatory approach may improve post-PCI risk stratification beyond either biomarker alone.
METHODS: Consecutive patients undergoing PCI between 2012 and 2022 were included and stratified according to baseline hs-CRP (≥2 mg/L vs <2 mg/L) and NLR (≥75th vs <75th percentile). The primary endpoint was 1-year major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to assess associations after adjustment for confounders.
RESULTS: Among 7,303 included patients, those with concomitantly elevated NLR and hs-CRP exhibited the highest incidence of overall MACE, followed by patients with only one elevated inflammatory marker, while the lowest event rates were observed in those with both markers below threshold. No significant interaction between NLR and hs-CRP was observed (P = .451). Elevated NLR was associated with a higher risk of MACE in both hs-CRP strata (hs-CRP ≥2 mg/L: hazard ratio 1.83, 95% confidence interval 1.42-2.35, P < .001; hs-CRP <2 mg/L: hazard ratio 1.55, 95% confidence interval 1.10-2.17, P = .012). After multivariable adjustment, this association remained significant only in patients with hs-CRP ≥2 mg/L, driven primarily by all-cause mortality and myocardial infarction.
CONCLUSION: In patients undergoing PCI, elevated NLR identifies a gradient of increasing risk, particularly when combined with hs-CRP ≥2 mg/L. A dual-marker inflammatory approach may improve post-PCI risk stratification beyond either biomarker alone.